MetaCap

Cellectar Biosciences Inc. (CLRB)

NASDAQ: CLRBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.797-0.1036 (-11.50%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CLRB stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.34
52-week range
0.7596 – 4.70
Day range
0.7596 – 0.90
Volume / Avg
80.36K / 97.96K
Beta
—

52-week range

$0.7596$4.70

CLRB stock today

Shares of Cellectar Biosciences (CLRB) finished lower on Nov 20 at $0.797, a drop of 11.50% or $0.1036 per share, versus the S&P 500's 3.70% decline. Shares are 83.0% below their 52-week high of $4.70, set on May 5, 2026 and 4.9% above the 52-week low of $0.7596, near the bottom of the past year's range. CLRB is down 73.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 72.1%.

Cellectar Biosciences has posted a net loss over the last twelve months (EPS of -$2.34), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cellectar Biosciences

Company profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. James V. Caruso
Headquarters
Florham Park, NJ
Employees
11

Financial highlights

Full financials

Cellectar Biosciences reported a net loss of $21.8 million, compared with a loss of $44.6 million a year earlier. Diluted earnings per share came in at -$8.35.

Cellectar Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-21.79M$-44.58M$-42.77M$-31.79M$-24.12M
EPS (diluted)$-8.35$-41.89$-3.50$-4.51$-4.35

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$11.50+1342.91%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $15.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.46 vs $-0.46

CLRB news

All CLRB news

Cellectar Biosciences peers

Health Care sector
CLRB peer companies
CompanyPrice% ChgMarket capCompare
DAREDare Bioscience Inc.0.4074-9.87%$8.01Mvs CLRB
PTNPalatin Technologies Inc.4.58-7.10%$8.16Mvs CLRB
PHIOPhio Pharmaceuticals Corp.0.656-8.25%$7.84Mvs CLRB
MBRXMoleculin Biotech Inc.7.74-2.40%$8.22Mvs CLRB
QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares1.29-9.15%$8.29Mvs CLRB
HINDVyome Holdings Inc.1.20-17.24%$8.42Mvs CLRB
VTGNVistagen Therapeutics Inc.0.1636-12.33%$7.56Mvs CLRB
LEXXLexaria Bioscience Corp.4.03-10.24%$8.49Mvs CLRB

Indexes, lists and sector

Cellectar Biosciences stock FAQ

What is Cellectar Biosciences's stock price today?

CLRB last traded at $0.797 as of Nov 20, 4:00 PM EST, down 11.50% on the day. Prices are delayed at least 15 minutes.

Does Cellectar Biosciences pay a dividend?

No. Cellectar Biosciences does not currently pay a regular cash dividend.

Who is Cellectar Biosciences's CEO?

Mr. James V. Caruso is the chief executive officer of Cellectar Biosciences Inc., which has about 11 employees.

Has CLRB ever split its stock?

Yes. The most recent CLRB stock split was a 1-for-30 split on Jun 24, 2025, one of 6 splits on record.

What is the CLRB 52-week high?

The 52-week high for CLRB is $4.70 and the 52-week low is $0.7596. The stock is currently 83.0% below its high.

Compare CLRB